Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04193878 · ClinicalTrials.gov registry record · Phase 3

ARrest RESpiraTory Failure From PNEUMONIA

A Phase 3 study, sponsored by Stanford University.

Terminated
Registry status
Phase 3
Development phase
465
Enrollment target

NCT04193878: Clinical Trial Phase 3 study, sponsored by Stanford University.

NCT04193878 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 465 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04193878, a Phase 3 study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
Phase 3
Development phase
465 participants
Enrollment target

Study Summary

This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

Primary Outcome

High flow nasal cannula (HFNC \>=20L/mon O2) and/or Noninvasive ventilation (NIV) use for greater than 36 hours OR Invasive mechanical ventilation for greater than 36 hours OR Death in a patient placed on respiratory support (HFNC, NIV, ventilator) who dies before 36 hours

Interventions

  • DRUG Inhaled placebo
  • DRUG Inhaled budesonide and formoterol

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2020-06-01
Est. Completion 2025-07-22
Phase Phase 3
Stanford University

1,744 total trials

Why NCT04193878 stopped before completion

NCT04193878 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 2 interventions - of which Inhaled placebo is the first listed.

NCT04193878 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04193878 about?

NCT04193878 is a clinical study titled "ARrest RESpiraTory Failure From PNEUMONIA". This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

What is the current status of trial NCT04193878?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2020-06-01. Estimated completion is 2025-07-22.

What interventions are being tested in trial NCT04193878?

The interventions under investigation include: Inhaled placebo (DRUG), Inhaled budesonide and formoterol (DRUG).

Who is sponsoring clinical trial NCT04193878?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04193878's enrollment target sits among peer trials

465 819th of 2000 higher than 1,180 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06717698 · 465 participants · Phase 2

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  • NCT07420283 · 465 participants · Phase 2

    A Study of Brenipatide in Participants With Opioid Use Disorder

  • NCT05312879 · 466 participants · Phase 2

    Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

  • NCT06917404 · 466 participants · Phase 3

    A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04193878, the US trial registry maintained by the National Library of Medicine. NCT04193878 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.